CD4+ T cells, primed by MHC class II presentation on APCs, can assist CD8+ T cells, induce MHC class I expression on cancer cells, activate myeloid cell cytotoxicity, and directly kill tumor cells [24,25]. This evidence concerns the gene CD4 and neoplasm.